Welcome to our dedicated page for Clearmind Medici news (Ticker: CMND), a resource for investors and traders seeking the latest updates and insights on Clearmind Medici stock.
Clearmind Medicine Inc. (CMND) is a clinical-stage biotech company advancing novel psychedelic-derived therapies for mental health and addiction disorders. This page provides investors and stakeholders with timely updates on the company’s progress in developing non-hallucinogenic treatments, including its MEAI-based therapeutic pipeline.
Access the latest press releases, clinical trial developments, and strategic partnership announcements. Stay informed about Clearmind’s expanding intellectual property portfolio, regulatory milestones, and research collaborations with leading institutions. Content spans preclinical updates, patent grants, and progress toward addressing conditions like alcohol use disorder (AUD) and binge behaviors.
Bookmark this page for direct access to verified CMND news, ensuring you stay current on advancements in psychedelic therapeutics. Check regularly for updates on the company’s mission to deliver safe, accessible treatments through rigorous clinical research and innovative science.
Clearmind Medicine Inc. (NASDAQ: CMND) has announced the formation of a Data and Safety Monitoring Board (DSMB) to oversee its first human clinical trial for treating Alcohol Use Disorder (AUD). This independent committee is composed of experts in internal medicine, psychiatry, and biostatistics, and is tasked with ensuring participant safety as well as data integrity throughout the trial. Dr. Adi Zuloff-Shani, CEO, emphasized the company's commitment to patient safety at all product development stages. Clearmind focuses on developing psychedelic-derived therapeutics for under-treated health conditions, supported by a portfolio of fourteen patent families aimed at advancing psychedelic compounds into regulated medical products.
Clearmind Medicine Inc. (NASDAQ: CMND) has filed a patent application with the USPTO for a novel combination of its psychedelic compound MEAI and SciSparc's Cannamide™ for treating depression. This development highlights Clearmind's commitment to expanding its intellectual property portfolio, which currently comprises 24 patents across 14 families, with 9 granted in major jurisdictions. The new patent aims to enhance treatment efficacy and safety for mental health disorders. Additionally, it aligns with the company's goal to create innovative solutions for under-treated health issues, including alcohol use disorder and obesity. This latest application demonstrates Clearmind's focus on developing regulated therapeutic options that could address significant patient needs.
Clearmind Medicine (NASDAQ: CMND) has announced significant progress towards its first-in-human clinical trial for the CMND-100 drug, aimed at treating Alcohol Use Disorder (AUD). The company has engaged a contract research organization (CRO) to support regulatory affairs, site selection, recruitment, and clinical monitoring. CMND-100 is based on Clearmind's proprietary MEAI molecule. CEO Dr. Adi Zuloff-Shani emphasized the company's commitment to advancing the trial, which targets a widely prevalent issue affecting many individuals. Clearmind's intellectual property portfolio includes fourteen patent families, and the company aims to expand it further. For more information, visit Clearmind's official website.
FAQ
What is the current stock price of Clearmind Medici (CMND)?
What is the market cap of Clearmind Medici (CMND)?
